Candel Therapeutics (CADL) Retained Earnings: 2020-2023
Historic Retained Earnings for Candel Therapeutics (CADL) over the last 3 years, with Sep 2023 value amounting to -$125.9 million.
- Candel Therapeutics' Retained Earnings fell 33.96% to -$125.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$125.9 million, marking a year-over-year decrease of 33.96%. This contributed to the annual value of -$99.1 million for FY2022, which is 23.41% down from last year.
- Latest data reveals that Candel Therapeutics reported Retained Earnings of -$125.9 million as of Q3 2023, which was down 7.18% from -$117.5 million recorded in Q2 2023.
- Over the past 5 years, Candel Therapeutics' Retained Earnings peaked at -$44.2 million during Q4 2020, and registered a low of -$125.9 million during Q3 2023.
- Moreover, its 3-year median value for Retained Earnings was -$89.7 million (2022), whereas its average is -$93.9 million.
- Data for Candel Therapeutics' Retained Earnings shows a maximum YoY tumbled of 81.78% (in 2021) over the last 5 years.
- Quarterly analysis of 4 years shows Candel Therapeutics' Retained Earnings stood at -$44.2 million in 2020, then tumbled by 81.78% to -$80.3 million in 2021, then dropped by 23.41% to -$99.1 million in 2022, then plummeted by 33.96% to -$125.9 million in 2023.
- Its Retained Earnings was -$125.9 million in Q3 2023, compared to -$117.5 million in Q2 2023 and -$107.9 million in Q1 2023.